INTRODUCTION
Cognitive impairment, such as memory loss (dementia), with increasing age is common and distressing to both the aged individual and their family [1] [2] [3] . Due to a gradual decline in cognitive capacity, patients with dementia are no longer able to continue their former regular occupational and social activities. Functional limitation restricts activities that are essential to daily living, such as bathing, dressing, toileting, and eating [4] . The physical and emotional impact of dementia caregiving is estimated to have resulted in healthcare costs of $9.1 billion in the United States in 2012 [5] .
A ''normal'', gradual, age-associated memory impairment (AAMI), with a decline of memory tasks by 50% or more over adulthood and aging, affects everybody [6] . Superimposed on this normal development, the majority of patients with dementia suffer from either a degenerative disease of the brain, mainly Alzheimer's disease (AD), or from multiple infarcts of the brain (vascular dementia), or from a combination of the two [6] . In a 65-year-old man, the remaining lifetime risk of AD has been shown to be 6.3%, and the risk developing any dementing illness to be 10.9%; with the corresponding risks for a 65-year-old woman of 12% and 19%, respectively [7] .
The distress associated with memory impairments, including AD, has ignited a search for viable treatments, and there have been various pharmacological or nutritional approaches explored to counter dementia [8, 9] .
Age-related cognitive deficits have been linked to various mechanisms, including cumulative oxidative stress and age-related changes in cellular metabolism [10] . Many age-related neurochemical changes can be traced to structural and functional alterations in neuronal membranes [11] . A decline of phospholipids-particularly phosphatidylserine (PS) in neuronal membranes-has been associated with memory impairment and deficits in mental cognitive abilities [12, 13] . This has led to the proposal that administration of endogenously occurring phospholipids may prevent or reverse age-related neurochemical deficits [14] .
The phospholipids PS and phosphatidic acid (PA) are found in the neuronal membrane in high concentrations and are essential to its functioning, acting as a biological detergent, and keeping fatty substances soluble and cell membranes flexible [15, 16] . PS was also found to reduce oxidative stress in the brain [17] , as well as to stimulate neurotransmitter release [18, 19] and to increase brain glucose metabolism [20, 21] . Experiments with PSsupplemented rodents have shown an improvement in memory, learning capacity, and other cognitive parameters [19, [22] [23] [24] [25] .
Several human studies have shown the efficacy of bovine brain-derived PS in patients with dementia [26] . For example, AAMI subjects were supplemented by three-month administration of bovine brain-derived PS, 300 mg daily [27] . An improvement on a number of neuropsychological tests was observed in the PS-supplemented subjects relative to those receiving placebo [27] . In a 12-week study with 149 AAMI patients, those supplemented with a bovine brain-derived PS formulation [100 mg PS three times daily (tid)]
improved, relative to placebo, in daily life learning and memory tasks [28] . In another 6-month double-blind study, 494 cognitively impaired elderly were supplemented with 300 mg bovine brain-derived PS daily (or placebo), resulting in a significant improvement in behavioral and cognitive parameters in the supplementation group [29] .
In a different study, placebo-controlled supplementation of elderly with 100 mg soy-PS six times daily (n = 41, PS-group) for 12 weeks did not reveal any significant cognitive improvements [30] . In contrast, a 12-week pilot study with 30 elderly volunteers suggested that soy lecithin-derived PS (100 mg tid) may have favorable effects on cognitive function in elderly with memory complaints [31] . Also, a different pilot study with 18 AAMI patients demonstrated significant positive effects on cognition [32] . A double-blind, randomized-controlled study investigating the effects of soy lecithin-derived PS on the cognitive functions of elderly Japanese subjects with memory complaints demonstrated (unlike placebo) significantly improved memory scores in PS-treated groups compared to baseline [33] .
In different studies, PS-containing preparations were found to selectively dampen stress levels in humans [34] [35] [36] , improve learning and perception parameters in children with attention-deficit hyperactivity disorder [37, 38] , and improve the calculation speed of athletes [39] . Due to concerns regarding bovine spongiform encephalopathy, the use of PS (and PA) produced by enzymatic conversion of soybean lecithin [40, 41] is considered a safer alternative. Although PS from both sources can be considered safe [42, 43] In the following, we describe pharmacokinetic data for soy lecithin-derived PS. Furthermore, the effect of dietary soy lecithin-derived PS?PA supplementation was evaluated in one uncontrolled and two placebo-controlled studies with elderly people with memory impairment or dementia, including AD (see Table 1 for an overview of the studies). The studies reported here were performed between 1992 and 1999 and were, to our knowledge, the first performed with plant-derived PS.
METHODS

Kinetic Analysis of Soy Lecithin-Derived PS
Standard soft gelatine capsules containing soy lecithin-derived PS and PA were supplied by Lipogen Ltd. (Haifa, Israel). The healthy Comparison of effects in two groups was performed for each parameter separately using the following methods: independent samples t test for after-before difference; analysis of variance in two groups with ''after'' values as an outcome and ''before'' values as a covariate.
RESULTS
Kinetic Analysis of Soy Lecithin-Derived PS
Serum analysis of eight overnight-fasted healthy volunteers (aged 28-52 years) after ingestion of soy lecithin-derived PS?PA was performed to assess the PS kinetics. The serum level of PS in relation to the level of total serum phospholipids before the intake was in the range of 1.8-2.2%, but it started increasing 30 min after ingestion, with a peak value 90 min after intake and returned to basal level 180 min after intake (Fig. 1) . The soy lecithinderived PS?PA was well-tolerated, with no side effects reported.
Study 1: Effect of PS1PA on Memory and Mood in Functioning Elderly
Study Population
Out of a total of 414 kibbutz members aged 60-80 years, 102 (24.6%) elderly reported some memory difficulties. After invoking the inclusion criteria, a total of 72 subjects of both sexes were included in the study, after they had submitted a written consent (40 PS?PA, 32 placebo). These non-depressed elderly with memory problems performed the following tests at baseline and after 3 months of PS?PA (n = 40) or placebo (n = 32) supplementation: (a) the WMS examined memory, learning, association, and information gathering;
(b) mood was tested using the LDS. At the end of 3 months, 57 participants could be retested (Fig. 2 , randomization scheme; Table 2 , characteristics of study population).
Fifteen subjects could not be located or dropped out due to death, non-compliance, or surgery. There were no statistically significant differences between the dropouts of the placebo group and the study group in any dimension examined. The characteristics of the placebo and supplementation groups are shown in Table 2 . The groups were found to be statistically comparable. Figure 3a shows that there was a significant testretest improvement in total WMS scores for both the PS?PA group and the placebo group. The changes were significant in both the placebo group (P\0.013) and the PS?PA group (P\0.005).
The WMS
Although no significant differences were found when comparing the scores between groups, further subgroup analysis shows that the initial WMS score had a significant effect on the change in the WMS score (Fig. 3b) . For those with a low initial score (\69), there was no significant difference between groups (P\0.91). However, for those with a higher initial WMS score ([68), those who received a placebo actually experienced a small score decrease after 3 months, whereas those who received PS?PA experienced a significant score increase; accordingly, there was a significant difference between groups (P\0.03). An analysis of the nine components that constitute the WMS score was performed: in the placebo group, a significant increase in the WMS score was found in the total score only (3.3%, P\0.03). However, in the PS?PA group, there was a highly significant increase not only in the total score (3.5%, P\0.001) but also in the test's components: information (2.2%, P\0.04), visual memory (10.6%, P\0.01), and memorizing numbers (7.0%, P\0.01).
Mood Changes: LDS
To assess mood changes after PS?PA administration, the score on the LDS was assessed before and after supplementation (Fig. 3c) . In a pre-post comparison, the results show that the placebo group experienced a significant increase in depressive symptoms between baseline (late summer) and the second time point (winter; P\0.001), whereas the PS?PA group revealed no significant change (P\0.4). The analyzed PP population was 39 people taking placebo, and 53 people taking PS?PA.
7-ADL Functioning Index
A comparison of the assessments of the 7-ADLs functioning index (Table 3) A positive effect could also be found in 7-ADL functioning change patterns rates (Table 3) Values are presented as n (%) unless otherwise stated AD Alzheimer's disease, ITT intention to treat, PA phosphatidic acid, PS phosphatidylserine, PP per protocol (P = 0.156; Fig. 4b ). However, trends could be observed: comparing the PS?PA group with the placebo group, there were higher rates of stability (32.7% vs. 24.2%, respectively) and improvement (44.9% vs. 33.3%, respectively).
Also, the deterioration was only approximately half as severe with 22.4% vs. 42.4%, respectively.
Self-Reported General Condition
The assessment of the self-reported general condition showed that 49.0% of patients in the PS?PA group reported an improvement in their general condition compared to 26.3% in placebo group (P = 0.084; Fig. 4c ).
Post-Trial Consumption Rate
The behavioral indicator of post-trial consumption rates revealed a large difference between the groups: 42.9% of the patients in the PS?PA group (6 of 14 assessed patients) decided to continue the supplementation at their own expense, in contrast to 0 of 11 in the placebo group (P = 0.010).
Safety and Tolerability
Regarding tolerability, 88.2% of the patients in PS?PA group and 91.1% of placebo group reported having no side effects at all. The remaining patients could not remember or had various sensations, most of which they could not relate directly to the supplementation. 
DISCUSSION
PS is a structural PL found in neuronal membrane and is essential to its functioning [15, 16] . In various studies, PS (mostly derived from bovine brain) was found to improve cognitive ability and functioning in demented patients (see ''Introduction''). However, the use of PS from a vegetative source, free of risk of encephalopathy, is considered advantageous, and the presented human studies were, to the best of our knowledge, the first to use plantderived PS.
The kinetic analysis in healthy volunteers demonstrated that soy lecithin-derived PS is absorbed and metabolized, with elevated serum levels for at least 1.5 h after an oral dose.
In Study 1 on 72 non-demented, nondepressed, functioning elderly with various degrees of AAMI, the post-supplementation memory testing scores in the PS?PA supplementation group were significantly higher than baseline, with a higher degree of significance compared to the placebo group. Furthermore, when preand postsupplementation results of components of the memory test were compared, none of the placebo group's changes were statistically significant, whereas results for maintaining information, visual memory, and memorizing numbers improved with statistical significance of P\0.05 within the PS?PA group. The nonsignificant improvement trends observed in the placebo group may be explained as a learning (test-retest) effect, and/or with the 4-8% of PA also contained within soy lecithin [49] .
Comparing both groups, we found that subjects who received PS?PA supplementation and who had scored high on the initial WMS showed more significant memory improvements, whereas those who had scored low did not. A probable explanation may be the rather small size of the study, as well as its relatively short duration. PS?PA was also observed to have clear beneficial effects in patients with dementia, especially if the expected gradual cognitive deterioration is taken into consideration:
In the placebo-controlled, randomized study involving patients with AD (Study 2), a statistically significant positive effect of PS?PA was found on the 7-ADLs functioning index, while a significantly more pronounced deterioration was revealed in the placebo group.
Functioning is considered to be highly important in geriatric practice, since it is strongly associated with pathology, and is a determinant of measurable outcomes, such as morbidity, mortality, hospitalization, and costs, as well as efficacy of interventions and treatments. The association of functioning 7-ADL 7 activities of daily living, PA phosphatidic acid, PS phosphatidylserine with quality of life and need of care is well established [50] .
The MMSE has a rather low sensitivity to minor changes [51] decided to continue the supplementation at their own expense after study termination, compared to none in the placebo group.
Similarly, many of those patients with dementia analyzed in a historical prospective manner continued PS?PA supplementation at their own expense for more than a year (data not shown).
In addition to the positive influence on the memory, the study on functioning elderly reveals a positive effect of PS?PA on mood. None of the participants in Study 1 had been initially depressed, since high LDS scores were excluded. Nevertheless, a worsening of mood with time was observed within the placebo group, which was not seen in the PS?PA supplementation group. ''Winter blues'', also known as seasonal affective disorder or seasonal depression, is a universal phenomenon in higher latitudes [52, 53] .
Since this study started in late summer and ended in winter, we suggest that soy lecithinderived PS?PA may be advantageous in prevention of ''winter blues'' and depression. Maggioni et al. [54] reported a positive effect of PS on geriatric depression. Dementia and mood are highly related, and sometimes dementia is accompanied by depression, thus the effects of PS on mood may be indirect effects due to the positive impact on cognition and memory.
CONCLUSION
Altogether our results suggest that PS?PA can support memory and cognitive function, which is especially apparent in those who have developed cognition deficiencies. Further investigations should assess a larger sample for a longer duration, so that the full and prolonged effects of PS?PA on cognition, memory, daily functioning, and mood in elderly and patients with dementia can be more thoroughly determined.
